TOKYO -- Eisai plans to increase its cash on hand by selling non-core operations and stepping up collection of accounts receivables, aiming to maintain its annual dividend of at least 150 yen per share.
Auto Immune drug has a 12 week that will continue for an additional 48 weeks. So we will get an update when the 12 week portion is done. They already had data showing it was best in class so to believe that it won't study out close to lab results might be a little pessimistic of you..... Even if it the study only shows it is 150% more effective then what is on the market that will still be great news....
Continue from my Mad post.
It might be why Jack was always so Cheeky and grinning. Like a kid in the candy store.... But unfortunately you have to prove your science and your drugs abilities through the Clinical Study programs, 3 of them. That takes good money management to get through those studies. It appears Jack was so impatient he brought them all through the pipeline at once. So they would all cross the finish line in a fairly small window. All of that would have been fine if his first failure was not so big and he did not refuse to address it. Had Eisai actually hit the 150 million to 200 million mark in sales on a yearly basis his plan would have worked. But Eisai was the wrong partner for the job. And to complicate matters he then sold the rights to the rest of the world to Eisai for pennies on the dollar, to deflect scrutiny and responsibility...
I think they have the science to back it up, they just have to prove it to the FDA and go through the motions and I believe it is why Jack did what he wanted and had his plan in place. He has a value in his mind and was not going to settle for anything less. Hell he blew off Pfizer a couple years ago, wanted too much according to Pfizer CEO.
Jack was going to develop the pipeline come hell or high water. Even to the point of sending low bidders away and not even notifying the BOD he had major interest and diluting the current shareholders. I am sure he felt the end would justify the means.
Ha Ha Ha these guys just pull stuff out of the eethers. IF you would care to read or do a little research you would know that your statement is wrong, not factual and no where near reality....
Short interest is up again
12/15/2015 , 25,669,891
11/30/2015 , 24,926,257
11/13/2015 , 24,340,204
10/30/2015 , 25,879,900
10/15/2015 , 29,092,766
9/30/2015 , 29,315,911
9/15/2015 , 25,801,024
Actually it looks like they are out of that bulk dry business now and are now in Oil Services. I am sure they will need oil above 40 to make any money,
In '07 the stock was over 100 bucks and a few short years ago it was over 4 bucks. It is tied to the dry shipping goods which are probably not doing so well.... Have not followed for quite some time. Wonder why it went all the way to .05 a share.
A R/S might be in their future.
They are not waiting for the CVOT, where do you come up with this garbage? You just make it up? The drug is already approved, not sure it needs as much scrutiny as the first round. It is the same drug only once a day formulation.....
According to Craig Audet, Belviq was the low hanging fruit and would generate enough cash flow to pay for the development of the entire pipeline. The miscalculation was not on Belviq but on our Partner Eisai, that became the World Wide marketer for Belviq.. They dropped the ball and screwed up at every corner.
Evidenced by the 150 million and 200 million projection made by L.C and Jack shortly after launch.
1. Bring back the uptick rule.
2. Locate shares to borrow before the short is allowed.
3. Report all short interest in real time. 3 days behind trade date.
4. Report firms that are short in real time. Or that are holding the shorts.
5. Make all FTD, failure to deliver close out immediately. Don't allow them to move the trade over and over extending their delivery date.
6. Penalize them financially for the FTD and if they continue to do it take their shorting privileges away.
7. Financially penalize the firm that allowed the short to happen without location. If they do it enough they lose their registration and are closed down. Less
I can show you many small bios being beat up until, they get their drugs to market and then the market can no longer lie and distort the facts. Shorting Bios is a high probability trade. Even more so in the past because most drugs never make it to approval and market. But that is where the real money is, being able to find the real science and drugs that will make it Buying them when the market is pricing them for BK and they succeed.
Nah, I believe a buyout comes when the Phase 2's are completed. Proof other then Belviq that their science works. Belviq alone is not enough with Eisai in control.
You have nothing to back that up. You have no inside knowledge and dont know how the studies will turn out. This is only your opinion. And you are betting against an entire company full of real science.
That is what Wall Street and shorts want everyone to focus on. But Arena is a drug development company all of their assests have value. Today they are counted as zero, a big mistake to believe that is worthless and bet that way.
When the games are done this will move as we go theiuth the weight loss season and get ti Phase 2 completions.
Belviq has over 70% insurance coverage. And a few major insurance companies are looking to see if it saves them money.
Give me a break. Belviq is safe and effective. That is why the FD approved the drug in the first place. Is that really all you got for bashing? You do realize that this is not going much lower and shorting a 2 dollar stock is very dangerous.
What are you going to do about it? Did you vote against the BOD last vote? Have you called or emails? Had your attorney send them a letter? If you have done nothing are you considering doing something other then posting on this MB?